Feuerstein disagrees with this (although I agree logically with it). I asked him this question specifically regarding ONTY pre-failure, and he wouldn't concede it. All he said was, "Who developed the drug? Merck kGaa or ONTY?"
What does the Feuerstein Rule say about the prospects of a prostate cancer drug that neither lowers PSA nor reduces tumor size? I hope I'm wrong, but 0% seems about right to me as I don't expect the Ph II survival advantage to hold up in Ph III. Hopefully, 427 will make OGXI an exception to Feuerstein's Retain Rule, which is why I remain long (and wrong).
They have not done a trial efficiency look yet and given 80/90% of the trial sites don't have acess to zytiga as part of the controll arm without -011 of the study there is a very high prabability that -011 is highly efficent in the chemo or zytiga/-011 cocktail.